Intravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular Age-Related Macular Degeneration Suboptimally Responsive to Antivascular Endothelial Growth Factor Agents: A Pilot Study from the Pan American Collaborative Retina Study Group

Página do item simplificado
dc.contributor.authorWu, Lihteh
dc.contributor.authorArevalo, J. Fernando
dc.contributor.authorHernandez-Bogantes, Erick
dc.contributor.authorRegatieri, Caio V. [UNIFESP]
dc.contributor.authorRoca, Jose A.
dc.contributor.authorFarah, Michel E. [UNIFESP]
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionKing Khalid Eye Specialist Hosp
dc.contributor.institutionJohns Hopkins Univ
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionClin Ricardo Palma
dc.date.accessioned2016-01-24T14:31:32Z
dc.date.available2016-01-24T14:31:32Z
dc.date.issued2013-04-01
dc.description.abstractPurpose: To compare the short-term visual and anatomic outcomes after intravitreal injections of 2 different tumor necrosis factor-a inhibitors to continued antivascular endothelial growth factor (VEGF) therapy in eyes with choroidal neovascularization (CNV) secondary to age-related macular degeneration that responded suboptimally to anti-VEGF agents.Methods: Retrospective comparative case series of 26 eyes. Eyes were injected intravitreally with 1 mg infliximab, 2 mg infliximab, 2 mg adalimumab, or 1.25 mg bevacizumab. the main outcomes measured were the best-corrected visual acuity (BCVA) and the central macular thickness (CMT) at 3 months of follow-up.Results: the mean log minimal angle of resolution BCVA changed from 1.04 +/- 0.23 at baseline to 1.06 +/- 0.51 at 3 months (P = 0.9455) in the 1-mg infliximab group; 0.94 +/- 0.48 at baseline to 0.85 +/- 0.43 in the 2-mg infliximab group (P = 0.2802); 1.58 +/- 0.50 at baseline to 1.38 +/- 0.43 in the adalimumab group (P = 0.1116); and 1.08 +/- 0.1 at baseline to 1.03 +/- 0.16 in the bevacizumab group (P = 0.9928). the mean CMT changed from 387 +/- 54 mm at baseline to 342 +/- 108 mm (P = 0.1053) in the 1-mg infliximab group; 301 +/- 42 mm at baseline to 284 +/- 73 mm (P = 0.4854) in the 2-mg infliximab group; remained unchanged at 348 +/- 106 mm (P = 0.308) in the adalimumab group; and 362 +/- 66 mm to 340-27 mm in the bevacizumab group (P = 0.4622). Adverse events included uveitis in 37.5% (6/16) of eyes injected with infliximab.Conclusion: Intravitreal infliximab and adalimumab do not appear to benefit eyes with CNV that responded suboptimally to anti-VEGF agents. Intravitreal injections of infliximab may elicit a severe intraocular inflammatory reaction.en
dc.description.affiliationInst Cirugia Ocular, San Jose 1225, Costa Rica
dc.description.affiliationKing Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia
dc.description.affiliationJohns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.affiliationClin Ricardo Palma, Dept Ophthalmol, Lima, Peru
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent366-371
dc.identifierhttp://dx.doi.org/10.1089/jop.2012.0203
dc.identifier.citationJournal of Ocular Pharmacology and Therapeutics. New Rochelle: Mary Ann Liebert Inc, v. 29, n. 3, p. 366-371, 2013.
dc.identifier.doi10.1089/jop.2012.0203
dc.identifier.issn1080-7683
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/36175
dc.identifier.wosWOS:000316947100017
dc.language.isoeng
dc.publisherMary Ann Liebert Inc
dc.relation.ispartofJournal of Ocular Pharmacology and Therapeutics
dc.rightsAcesso restrito
dc.titleIntravitreal Tumor Necrosis Factor-Alpha Inhibitors for Neovascular Age-Related Macular Degeneration Suboptimally Responsive to Antivascular Endothelial Growth Factor Agents: A Pilot Study from the Pan American Collaborative Retina Study Groupen
dc.typeArtigo
Arquivos
Coleções
Em verificação - Geral